Business
Zelluna ASA activates first clinical site for ZIMA-101, marking entry into clinical execution
Oslo, 6 May 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today announces that the first clinical site in the ZIMA-101 Phase 1 trial has now been activated. This marks the transition of the study from clinical preparation to active trial execution of the ZIMA-101 study. The first activated clinical site is The Christie NHS Foundation Trust in the United Kingdom, where Pr
About this update from Zelluna Asa
[{"type":"image","alt":"Zelluna ASA","displaySize":"","headline":null,"caption":"Zelluna ASA","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":106,"url":"https://media.zenfs.com/en/globenewswire.com/a3f855525ffb13acd9e8579786771e69"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/iTbKZt.BH3X6HDy05KDjtQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0OA--/https://media.zenfs.com/en/globenewswire.com/a3f855525ffb13acd9e8579786771e69","width":300,"height":106},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/iTbKZt.BH3X6HDy05KDjtQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0OA--/https://media.zenfs.com/en/globenewswire.com/a3f855525ffb13acd9e8579786771e69","width":300,"height":106}},"lazy":false},{"type":"text","content":"Oslo, 6 May 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today announces that the first clinical site in the ZIMA-101 Phase 1 trial has now been activated.","length":308,"tagName":"p"},{"type":"text","content":"This marks the transition of the study from clinical preparation to active trial execution of the ZIMA-101 study.","length":113,"tagName":"p"},{"type":"text","content":"The first activated clinical site is The Christie NHS Foundation Trust in the United Kingdom, where Professor Fiona Thistlethwaite serves as Chief Investigator for the study.","length":184,"tagName":"p"},{"type":"text","content":"ZIMA-101 is a first-in-human Phase 1 trial evaluating ZI-MA4-1, Zelluna’s lead TCR-NK product candidate.","length":109,"tagName":"p"},{"type":"text","content":"On 20 February 2026, Zelluna announced that the Medicines and Healthcare products Regulatory Agency (MHRA) and Research Ethics Committee (REC) had approved the Company’s Clinical Trial Application (CTA) for ZIMA-101 in the UK.","length":251,"tagName":"p"},{"type":"text","content":"Activation of the second clinical site, The Royal Marsden, is expected in the near term.","length":93,"tagName":"p"},{"type":"text","content":"“This is an important milestone for Zelluna. With the first clinical site now activated, we are entering the execution phase of the ZIMA-101 study. Our focus is now on advancing clinical execution, including patient screening and progression towa...